Frequently asked questions
Your questions, answered.
The most common questions about pharmacogenomic testing and our genomic analyses.
What is a pharmacogenomic test?
A pharmacogenomic test examines how your genes affect the way your body processes certain medicines and how you respond to them. The result helps your physician choose the right drug and dose.
Who is the test for?
It is especially useful for people starting a new medicine, not responding to a medicine as expected, experiencing side effects, or taking several medicines. Your physician decides whether the test is appropriate.
How is the test performed?
A simple blood sample taken on your physician’s request is sufficient. The sample is analysed at the responsible medical genetics diagnostic centre.
Does my genotype change over time?
No. Your genotype does not change during your lifetime, so the result remains a reference for medicines prescribed in the future. Interpretations may change as guidelines are updated.
Should I stop my medicine based on the result?
No. Never stop a medicine or change its dose on your own. Always review your results with your physician.
Which drugs are covered?
With our 67-locus panel, more than 270 drugs across 23 clinical areas are assessed using CPIC, DPWG and FDA recommendations.
How is it different from other pharmacogenomic tests?
Most tests look only at a few predefined positions. We sequence the coding regions of the genes, call known alleles, and separately assess unexpected variants within the ACMG framework. We have custom calling modules for CYP2D6 and HLA.
What is the difference between WES, CES and Trio-WES?
WES examines the coding regions of about 20,000 genes. CES focuses on genes with known disease associations. Trio-WES analyses the patient’s exome together with both parents’, directly revealing de novo variants and inheritance patterns.
How is my data protected?
Genetic data is special-category personal health data and is protected under Turkish data protection law (KVKK). Our analyses run locally with restricted external connections.
In which languages are reports available?
Reports are prepared in Turkish and can be produced in other languages and tailored by clinical specialty on request.
Is the test IVD-approved?
Our pharmacogenomic report is a clinical decision-support document for physicians. It is for research use and is not IVD-approved.